PFBT
HRTX icon

Parkside Financial Bank & Trust’s Heron Therapeutics HRTX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240 Buy
+560
New +$449 ﹤0.01% 2661

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Parkside Financial Bank & Trust's HRTX Position: Q2 2026 in Review

Parkside Financial Bank & Trust opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 560 shares worth $240. The stake represents ﹤0.01% of the portfolio and ranks #2661 among its holdings.

163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Parkside Financial Bank & Trust held 560 shares of Heron Therapeutics worth $240 as of Q2 2026.
  • Heron Therapeutics was a new Parkside Financial Bank & Trust position in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2661 holding.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.